StreetAlpha.app
Home › Stocks › LQDA

Liquidia Corp (LQDA)

Healthcare
$56.73
▲ +0.64%
LAST CLOSE · NOV 17

Liquidia is a biopharmaceutical company that sells YUTREPIA, an inhaled treprostinil treatment for pulmonary arterial hypertension. It last closed at $56.73 on Nov 17, up 0.64% on the day. LQDA last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 7 analysts is $63.29 (+11.6% from the last close), with a high of $87.00 and a low of $40.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 9 whale options trades in LQDA, 44% of them bullish and 56% bearish. In the past 30 days there were 2 dark pool prints totaling $2.3M, the largest $1.5M.

AI Auto Pilots
Is LQDA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$621.9M
+798.4% vs a year ago
Net income
−$94.2M
−15.1% margin
EPS (diluted)
−$1.05
Free cash flow
$291.2M
46.8% margin
Valuation
Market cap
$5.1B
90.1M shares
P/E
–
No P/E while losing money
Price to sales
8.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$396.1M
At Sep 30
Shareholder equity
−$25.4M
Shares outstanding
90.1M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $12.9M$12.9MFY2021FY2022: $15.9M$15.9MFY2022FY2023: $17.5M$17.5MFY2023FY2024: $14.0M$14.0MFY2024FY2025: $158.3M$158.3MFY2025

From LQDA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · Before the open (BMO)
Reported EPS
-$0.04
vs $0.77 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±8.6%
Priced in before that report
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
6 Buy1 Hold0 Sell
Each firm's latest rating on LQDA in the past 90 days
Average 12-month target
$63.29
▲ 11.6% upside

Based on 7 analysts who set a price target on LQDA in the past 90 days. The average target is $63.29, with a high of $87.00 and a low of $40.00, compared with the last close of $56.73.

$21$46$71$96PAST 99 TRADING DAYS12-MONTH TARGETSHIGH $87AVG $63.29LOW $40May 22LAST CLOSE+12 MO$21$46$71$96PAST 99 DAYSTARGETSHIGH $87AVG $63.29LOW $40May 22LAST CLOSE+12 MO
Highest target$87.00
Average target$63.29
Lowest target$40.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 13Buy$76
Wells FargoTarget raised
Nov 11Hold$33 → $40
NeedhamTarget raised
Nov 11Buy$58 → $66
JefferiesMaintained
Nov 10Buy$62
BTIGTarget raised
Nov 10Buy$70 → $87
DateFirmActionRatingPrice target
Nov 13HC Wainwright & Co.Assumed coverageBuy$76
Nov 11Wells FargoTarget raisedHold$33 → $40
Nov 11NeedhamTarget raisedBuy$58 → $66
Nov 10JefferiesMaintainedBuy$62
Nov 10BTIGTarget raisedBuy$70 → $87
Loading…

Technical Analysis

LQDA · as of the Nov 17 close · updated after every close
Turning up, nearing overbought

The stock is 16% above its 20 day and 15% above its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 65), near overbought. The nearest support is the Pivot at $56.24, and the nearest resistance the Pivot R1 at $57.69.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNear overbought
VolatilityHigh, 6.6%/day
Key levels
$93.6152 week high+65.0%
$63.46Swing high (May 27)+11.9%
$63.39100 day average+11.7%
$57.69Pivot R1+1.7%
$56.73Last close
$56.24Pivot−0.9%
$55.28Pivot S1−2.6%
$54.85200 day average−3.3%
$53.06Swing low (Jun 3)−6.5%
$48.5050 day average−14.5%
$47.4820 day average−16.3%
$22.3152 week low−60.7%
Indicators
RSI (14)65.36Strong, overbought above 70Neutral
MACD3.24Above its signal lineBullish
Stochastic85.2Near the top of its rangeOverbought
ADX (14)30.8Trending up
Williams %R-15.4Oversold below −80, overbought above −20Overbought
CCI (20)122.2Oversold below −100, overbought above 100Overbought
Rate of change+34.4%Change over 10 sessionsBullish
ATR (14)$3.73Typical daily range, 6.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for LQDA

What happened before

See how LQDA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed4 bullish and 5 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow LQDA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LQDA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
9
Bullish
4
44%
Bearish
5
56%
Date span
Sep 11 – Oct 20
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.3M
Largest print
$1.5M
Loading…

LQDA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●179 buying vs 188 selling
  • ▲Held by funds +2.9 pts
  • ▼Funds holding -35
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call 1.57 to 1.62
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding305340−10.3%
In funds' top 10813−38.5%
Held by funds83.6%80.7%+2.9 pts
New / increased63 / 116127 / 103−22.2%
Reduced / sold out93 / 9582 / 34+62.1%
Put/call ratio1.621.57+3.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LQDA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LQDA is in one of them and how their past LQDA trades turned out.

LQDA in the AI portfolios
Loading…

LQDA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LQDA in an article yet. Here's the latest on the wider market.

LQDA Congress Trades

All congress trades →
Trades, 12 months
3
Buys
0
0%
Sells
3
100%
People
1
Last filed Sep 22
Who traded LQDA · since 2026
Latest 3 filings
$15K – $50KTraded Aug 31, 2026Filed Sep 22, 2026
$50K – $100KTraded Jul 29, 2026Filed Sep 22, 2026
$1K – $15KTraded Jul 8, 2026Filed Sep 22, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KAug 31, 2026Sep 22, 202622 d
Donald J TrumpExecutive branchSell$50K – $100KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$1K – $15KJul 8, 2026Sep 22, 202676 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Liquidia

Liquidia is a biopharmaceutical company based in Morrisville, North Carolina, that develops and sells medicines for lung and blood vessel diseases. Its main product is YUTREPIA, an inhaled treprostinil powder used to treat pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. The company also shares profits from a generic treprostinil injection sold in the United States and is developing other treatments, including for pulmonary hypertension linked to COPD. Its customers include healthcare providers who treat these patients and the organizations that distribute and pay for these medicines.

Headquarters
Morrisville, NC